Table 1. Clinical patient characteristics, n=559.

Age at first diagnosis
Median, years	49
Range	(14–92)
FIGO stage
IA/B	279 (49.9%)
IC	134 (24.0%)
IIA-C	65 (11.6%)
IIIA-C	81 (14.5%)
Primary surgical approach
Laparoscopy	198 (35.4%)
Converted laparoscopy	54 (9.7%)
Laparotomy	307 (54.9%)
Histologic characteristics
Stromal microinvasion	30 (5.4%)
Micropapillary pattern	85 (15.2%)
Surgical procedures in primary and re-staging surgerya
Bilateral salpingo-oophorectomy	450 (80.5%)
Unilateral salpingo-oophorectomy	135 (24.2%)
Cystectomy	103 (18.4%)
Hysterectomy	398 (71.2%)
Omentectomy	438 (78.4%)
Peritoneal biopsies	374 (66.9%)
Cytology	382 (68.3%)
Appendectomy	165 (29.5%)
Pelvic LND/LN biopsies	118 (21.1%)
Para-aortic LND/LN biopsies	77 (13.8%)
Peritoneal implants in primary or re-staging surgery
None	428 (76.6%)
Non-invasive	110 (19.7%)
Invasive	21 (3.8%)
Surgical cytoreduction
Complete	517 (92.5%)
Incomplete	8 (1.4%)
Unknown	34 (6.1%)
Staging quality after primary surgery
Adequate	164 (29.3%)
Inadequate	395 (70.7%)
Staging quality after primary and re-staging surgery
Adequate	278 (49.7%)
Inadequate	281 (50.3%)
Fertility-sparing surgery
Yes	110 (19.7%)
No	449 (80.3%)
Up-staging after re-staging surgery
Yes	29 (5.2%)
No	530 (94.8%)
Recurrent disease
Yes	53 (9.5%)
Borderline tumour	40/53 (75.5%)
High grade carcinoma	4/53 (7.5%)
Low grade carcinoma	8/53 (15.1%)
Unknown	1/53 (1.9%)
No	506 (90.5%)
Site of recurrent diseasea
Ovarian tissue	26/53 (49.1%)
Ipsilateral	9/53 (17.0%)
Contralateral	20/53 (37.7%)
Peritoneum	28/53 (52.8%)
Omentum	1/53 (1.9%)
Other	2/53 (3.8%)
Unknown	10/53 (18.9%)
Malignant transformation during follow-up
Yes	13/53 (24.5%)
No	40/53 (75.5%)
5-year progression-free survival	86.9%
5-year disease-specific survival	99.2%

Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; LND=lymph node dissection; LN=lymph node.

^aMultiple entries possible.